BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 11, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» New TCR T-cell therapy targeting ROPN1 is a promising candidate for TNBC
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
New TCR T-cell therapy targeting ROPN1 is a promising candidate for TNBC
May 8, 2023
No Comments
Around 73,000 women are diagnosed with triple-negative breast cancer (TNBC) every year in the U.S. and EU. TNBC grows and spreads faster than other types of breast cancer; moreover, it has less treatment options, and usually, a worse prognosis.
BioWorld Science
Conferences
Cancer
Immuno-oncology